clinical trial · NCT03556592
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
LEO Pharma·phase1·completed·n = 40
Atopic DermatitisTralokinumabCaffeineWarfarinOmeprazoleMetoprololMidazolam Hydrochloride
brief summary
The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after: * 14 weeks of treatment with tralokinumab * a single dose of tralokinumab
started
Aug 13, 2018
primary completion
Mar 16, 2020
completion
Jun 20, 2020
last updated
Feb 24, 2025
official title
An Open-label, Multi Centre Drug-drug Interaction Trial to Investigate the Effects of Tralokinumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Subjects With Moderate-to-severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol